Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Shigehisa TAMAKI"'
Autor:
Hideo Wada, Katsuya Shiraki, Takeshi Matsumoto, Hideto Shimpo, Yumi Sakano, Hiroko Nishii, Shigehisa Tamaki, Kei Suzuki, Isao Tawara, Yoshiki Yamashita, Motomu Shimaoka
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 13, p 3857 (2024)
Background/Objectives: FVIII reagent activity varies across different assays, as well as activated partial thromboplastin time (APTT) reagents. The hemostatic ability of various FVIII reagents was examined via clot waveform analysis (CWA). Methods: A
Externí odkaz:
https://doaj.org/article/0f9fed84d2fb4be989e38d9c19bdef49
Autor:
Yuji Okamoto, Mitsuhito Hirano, Kai Morino, Masashi K. Kajita, Shinji Nakaoka, Mayuko Tsuda, Kei-ji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa, Seiichi Shimizu, Toshiaki Yujiri, Hisashi Wakita, Kaichi Nishiwaki, Arinobu Tojo, Kazuyuki Aihara
Publikováno v:
npj Systems Biology and Applications, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the BCR-ABL1 tyrosine kinase. Although ABL1-specific tyrosine kinase inhibitors (TKIs) including nilotinib have dramatically improved the prognosis of patients with CM
Externí odkaz:
https://doaj.org/article/58f4e055c3eb45ed81510406b1170155
Autor:
Kaichi Nishiwaki, Kei‐ji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa, Seiichi Shimizu, Toshiaki Yujiri, Arinobu Tojo, Hisashi Wakita
Publikováno v:
Cancer Medicine, Vol 9, Iss 11, Pp 3742-3751 (2020)
Abstract For patients who have chronic myeloid leukemia (CML), one of the primary treatment options is administration of nilotinib 300 mg twice daily (BID). In previous studies which compared outcomes associated with nilotinib or imatinib treatment,
Externí odkaz:
https://doaj.org/article/d6cec3dbf9054fe0b643aba4e9c79cd9
Autor:
Akihiro Takeshita, Norio Asou, Yoshiko Atsuta, Hiroaki Furumaki, Toru Sakura, Yasunori Ueda, Masashi Sawa, Nobuaki Dobashi, Yasuhiro Taniguchi, Rikio Suzuki, Masaru Nakagawa, Shigehisa Tamaki, Maki Hagihara, Katsumichi Fujimaki, Hitoshi Minamiguchi, Hiroyuki Fujita, Masamitsu Yanada, Yoshinobu Maeda, Noriko Usui, Yukio Kobayashi, Hitoshi Kiyoi, Shigeki Ohtake, Itaru Matsumura, Tomoki Naoe, Yasushi Miyazaki, the Japan Adult Leukemia Study Group
Publikováno v:
Cancers, Vol 12, Iss 6, p 1444 (2020)
Background: After long-term analysis of the JALSG-APL204 study we recently reported that maintenance therapy with tamibarotene was more effective than all-trans retinoic acid (ATRA) by reducing relapse in APL patients. Here, the clinical significance
Externí odkaz:
https://doaj.org/article/aebcdb6e50ea4cdbbbb66af997b35a70
Autor:
Masahiro Hirayama, Eiichi Azuma, Atsuko Nakagawa-Nakazawa, Tadashi Kumamoto, Shotaro Iwamoto, Keishiro Amano, Shigehisa Tamaki, Eiji Usui, Yoshihiro Komada
Publikováno v:
Haematologica, Vol 98, Iss 1 (2013)
Although there are National Institutes of Health consensus criteria for the global assessment of chronic graft-versus-host disease, no validated biomarkers have been established for this disease. Furthermore, whereas the role of T cells, B cells, and
Externí odkaz:
https://doaj.org/article/74cd11560ad14ac499cff02fd3415f6e
Autor:
Keiki Nagaharu, Takuya Izumi, Mitsuko Maruyama, Yuka Sugimoto, Kohshi Ohishi, Isao Tawara, Eiji Usui, Shigehisa Tamaki
Publikováno v:
Internal Medicine; 2024, Vol. 63 Issue 9, p1273-1275, 3p
Autor:
Kaho, Kodama, Maki, Hamaguchi, Eiji, Yamada, Nobuyuki, Tsuda, Keiko, Sugimoto, Saori, Nakamura, Toshiaki, Kobayashi, Shoulin, Wang, Hirohito, Minami, Atsushi, Fujieda, Masato, Shikami, Takashi, Okamoto, Takehisa, Ohnishi, Noriko, Ii, Shigehisa, Tamaki
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 63(11)
A 78-year-old man with prostate squamous cell carcinoma recurrence in his pelvis was admitted to our hospital. Rectal obstruction led to creation of an artificial anus on the transverse colon. Then, docetaxel and radiation therapies were started. A w
Autor:
Yoshinobu Aisa, Masao Hagihara, Rika Sakai, Yotaro Tamai, Naohi Sahara, Eri Tanaka, Koji Miyazaki, Atsushi Wake, Ryuji Ishii, Shigehisa Tamaki, Morihiro Inoue, Kenji Tajika, Takeshi Kobayashi, Masaaki Higashihara, Shin Fujisawa, Tomonori Nakazato, Seiji Irie, Jian Hua
Publikováno v:
Annals of Hematology. 100:2745-2754
The Vulnerable Elders Survey-13 (VES-13) is a well-studied simplified frailty screening tool for elderly patients in the oncology setting. We conducted a prospective clinical trial to evaluate the efficacy and safety of dose-adjusted treatment based
Publikováno v:
Annals of hematology. 101(12)
Autor:
Isao Tawara, Maki Nakamura, Kaname Nakatani, Ikeda T, Yuka Sugimoto, Shigehisa Tamaki, Naoyuki Katayama, Keiki Nagaharu, Kohshi Ohishi, Minoru Mizutani, Makoto Ikejiri
Publikováno v:
International Journal of Hematology. 113:618-621
MPL exon 10 mutations are one of the driver mutations in essential thrombocythemia (ET) or myelofibrosis (MF). We have established an in-house MPL mutation analysis system, covering the entire region of MPL exon 10 by direct sequencing. Since 2009, M